Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ABBV

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program.

Benzinga

Should You Buy This Blue-Chip Dividend Stock at Record Highs?

AbbVie shares have hit record highs after extending Rinvoq’s patent protection to 2037, boosting confidence in future earnings and dividend growth, with analysts seeing steady fundamentals and modest upside as the company’s immunology pipeline drives results.

Barchart

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The 5 Best Dividend Stocks to Buy for Steady Income in 2025

Here are five “set-and-forget” dividend stocks.

Barchart

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie Inc. (NYSE:ABBV) stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, marketed by the company as Rinvoq.

Benzinga

Is AbbVie Stock Underperforming the S&P 500?

AbbVie has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Barchart

Read news from The Economist, FT, and more,
with one subscription

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

MarketBeat

AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment

AbbVie Inc. (NYSE:ABBV) announced Monday that it will acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate for moderate-to-severe major depressive disorder (MDD).

Benzinga

AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib

AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean…

Benzinga

AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules

AbbVie Inc. (NYSE:ABBV), the manufacturer of Imbruvica, is at the center of a constitutional challenge to the federal government's new Drug Price Negotiation Program.

Benzinga

AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?

Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

Benzinga

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Benzinga

My Top 2 Earnings Picks For This Earnings Season

This morning, I woke up to the sound of pounding rain on the roof of my bus and a generator that made me decide to take the day off. Add in some flash flooding, a Wi-Fi signal riding on Starlink, and it's already been a day to remember.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Here's What to Expect From AbbVie's Next Earnings Report

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Barchart

How Is AbbVie's Stock Performance Compared to Other Pharmaceuticals Stocks?

AbbVie has outperformed the Pharmaceuticals industry over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Johnson & Johnson Stock: Is JNJ Outperforming the Healthcare Sector?

Johnson & Johnson has outpaced the broader healthcare sector over the past year, and analysts remain optimistic about the stock’s prospects.

Barchart

Options Action: 3 Iron Condor Ideas Amid Market Volatility

With volatility remaining stubbornly high, option premiums are elevated which could mean it’s a great time for iron condor trades.

Barchart

Bearish Outlook? Try These 2 Bear Call Spread Trades on Tuesday

If you feel like the market is due for a pause here, then you’re in luck, as there is still a way to profit using options. In this article, we'll show you two bear call spread trades you can make this Tuesday.

Barchart

Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?

AbbVie has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From AbbVie's Report

AbbVie is scheduled to report its first-quarter results this month, with analysts anticipating a modest growth in earnings.

1 2 3 4 5

People

Warren Buffett

1,931 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.